Karina Cicinelli, Corporate Medical Director at Adium.
Today, we have a new treatment option for patients with MCL, MZL and WM in Uruguay, providing hope for improved treatment outcomes," said Dr. "Tolerability of treatments for B-cell malignancies is an important consideration with BTK inhibition, and BRUKINSA was designed with that in mind to maximize BTK occupancy and minimize off-target binding. BeiGene and Adium entered into an exclusive distribution agreement for Adium to commercialize BRUKINSA in Latin America. MONTEVIDEO, Uruguay & CAMBRIDGE, Mass & BEIJING, April 28, 2022-( BUSINESS WIRE)-BeiGene (NASDAQ: BGNE HKEX: 06160 SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the BTK inhibitor BRUKINSA (zanubrutinib) has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma (MCL), relapsed or refractory marginal zone lymphoma (MZL), and Waldenström’s macroglobulinemia (WM). Under an exclusive distribution agreement, Adium will commercialize BRUKINSA in Latin America
BRUKINSA is now available in four countries in Latin America, following previous approvals in Brazil, Chile, and Ecuador
0 kommentar(er)
